-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$22.67123.13% Upside
KalVista Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover KalVista Pharmaceuticals, Inc.?
KalVista Pharmaceuticals, Inc. has been rated by research analysts at Needham, H.C. Wainwright, Leerink Partners in the past 90 days.